Christopher Gottschalk, MD

home / authors / christopher-gottschalk-md

Articles

The Changing Landscape of Preventative Migraine Treatments

Jessica Ailani, MD;Stephanie J. Nahas, MD, MSEd;Rebecca Erwin Wells, MD, MPH;Andrew C. Charles, MD;Christopher Gottschalk, MD

January 14th 2022

A panel of expert neurologists shares advice for community neurologists on preventive migraine treatment and exciting therapies to look forward to.

Headache Specialists for Preventative Migraine Treatments

Jessica Ailani, MD;Stephanie J. Nahas, MD, MSEd;Rebecca Erwin Wells, MD, MPH;Christopher Gottschalk, MD;Andrew C. Charles, MD

January 7th 2022

A discussion on when a patient should be referred to a headache specialist for preventive migraine treatment.

Preventative Migraine Therapies: The ADVANCE Trial and the Future

Jessica Ailani, MD;Rebecca Erwin Wells, MD, MPH;Christopher Gottschalk, MD;Stephanie J. Nahas, MD, MSEd;Andrew C. Charles, MD

January 7th 2022

Jessica Ailani, MD, details how the phase 3 ADVANCE trial will shape the research of future agents for preventive migraine treatment.

Oral Agents for Preventative Migraine Treatment

Jessica Ailani, MD;Andrew C. Charles, MD;Stephanie J. Nahas, MD, MSEd;Christopher Gottschalk, MD;Rebecca Erwin Wells, MD, MPH

December 31st 2021

A key opinion leader discusses the use of oral agents for the preventive treatment of migraine.

CGRP Monoclonal Antibodies and Patient Treatment Selection

Jessica Ailani, MD;Stephanie J. Nahas, MD, MSEd;Rebecca Erwin Wells, MD, MPH;Andrew C. Charles, MD;Christopher Gottschalk, MD

December 31st 2021

Dr Christopher Gottschalk shares how the clinical trial data for CGRP monoclonal antibodies affect patient selection for preventive migraine treatment.

CGRP Monoclonal Antibodies: A Review of Trial Data

Jessica Ailani, MD;Andrew C. Charles, MD;Christopher Gottschalk, MD;Stephanie J. Nahas, MD, MSEd;Rebecca Erwin Wells, MD, MPH

December 24th 2021

A panel of neurologists review clinical trial data on several CGRP monoclonal antibodies for migraine preventive treatment.

Preventing Migraine with CGRP Monoclonal Antibodies

Stephanie J. Nahas, MD, MSEd;Jessica Ailani, MD;Christopher Gottschalk, MD;Rebecca Erwin Wells, MD, MPH;Andrew C. Charles, MD

December 24th 2021

Expert neurologists discuss the use of CGRP monoclonal antibodies to prevent migraines.

OnabotulinumtoxinA for Preventative Migraine Treatment

Jessica Ailani, MD;Andrew C. Charles, MD;Christopher Gottschalk, MD;Rebecca Erwin Wells, MD, MPH;Stephanie J. Nahas, MD, MSEd

December 17th 2021

Stephanie J. Nahas, MD, MSEd, FAHS, FAAN, provides an overview of the use of onabotulinumtoxinA as a preventive migraine treatment.

Discussing Novel Agents for Preventative Migraine Therapy with Patients

Jessica Ailani, MD;Christopher Gottschalk, MD;Andrew C. Charles, MD;Rebecca Erwin Wells, MD, MPH;Stephanie J. Nahas, MD, MSEd

December 17th 2021

A thought leader explains how she involves the patient when selecting novel agents to add to a preventive migraine treatment plan.

Preventative Migraine Therapy: Novel Agents

Jessica Ailani, MD;Christopher Gottschalk, MD;Stephanie J. Nahas, MD, MSEd;Rebecca Erwin Wells, MD, MPH;Andrew C. Charles, MD

December 10th 2021

An introduction to the use of novel agents for preventive migraine therapy.

Behavioral Treatment Strategies for Migraine Management

Jessica Ailani, MD;Christopher Gottschalk, MD;Andrew C. Charles, MD;Rebecca Erwin Wells, MD, MPH;Stephanie J. Nahas, MD, MSEd

December 10th 2021

An expert panel discusses migraine prevention with the use of behavioral therapies such as cognitive behavioral therapy and stress management.

Discussing Preventative Migraine Lifestyle Changes with Patients

Jessica Ailani, MD;Christopher Gottschalk, MD;Stephanie J. Nahas, MD;Rebecca Erwin Wells, MD, MPH;Andrew C. Charles, MD

December 3rd 2021

Dr Andrew Charles shares how he eases patient anxieties over lifestyle changes for preventive migraine therapy.

Non-Drug Therapies for Migraine Prevention: Lifestyle Changes

Jessica Ailani, MD;Christopher Gottschalk, MD;Andrew C. Charles, MD;Rebecca Erwin Wells, MD, MPH;Stephanie J. Nahas, MD

December 3rd 2021

Rebecca Erwin Wells, MD, MPH, details the effectiveness of lifestyle changes for preventative migraine treatment.

Measuring Success in Migraine Preventative Treatment

Jessica Ailani, MD;Rebecca Erwin Wells, MD, MPH;Stephanie J. Nahas, MD, MSEd;Christopher Gottschalk, MD;Andrew C. Charles, MD

November 26th 2021

A discussion on how to measure the success of preventative migraine treatment.

Migraine Preventative Treatment and Burden of Disease

Jessica Ailani, MD;Andrew C. Charles, MD;Stephanie J. Nahas, MD, MSEd;Christopher Gottschalk, MD;Rebecca Erwin Wells, MD, MPH

November 26th 2021

Key opinion leaders explain the burden of disease that accompanies preventative migraine treatment.

Goals of Preventative Therapy for Migraine

Jessica Ailani, MD;Andrew C. Charles, MD;Stephanie J. Nahas, MD;Christopher Gottschalk, MD;Rebecca Erwin Wells, MD, MPH

November 19th 2021

Expert neurologists share their goals and patient considerations for preventive migraine therapy.

Migraine: A Historic Perspective on Preventative Therapy

Jessica Ailani, MD;Stephanie J. Nahas, MD;Christopher Gottschalk, MD;Andrew C. Charles, MD;Rebecca Erwin Wells, MD, MPH

November 19th 2021

Andrew C. Charles, MD, provides a historical perspective on the agents traditionally used for preventive migraine therapy.

Christopher Gottschalk, MD: Long-Term Safety in Preventive Migraine Therapies

Christopher Gottschalk, MD

July 25th 2019

The director of headache medicine and chief of general neurology at Yale Medicine discussed the long-term success the new preventive migraine therapies have shown thus far, and how the lack of safety concerns will improve how they’re utilized.

Christopher Gottschalk, MD: Advantages of Eptinezumab and CGRP Inhibitors

Christopher Gottschalk, MD

July 14th 2019

The director of headache medicine and chief of general neurology at Yale Medicine spoke about the significance of having CGRP inhibitors in migraine treatment, and how eptinezumab fits into the treatment landscape.